Pascal Deschatelets - 28 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: APLS
Reported as of: 28 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jan 2026, 16:10:56 UTC
Prior SEC filing: 23 Jan 2026
Next SEC filing: 14 May 2026
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 30 Jan 2026.

Key facts

This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Jan 2026, 16:10.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001657720 Primary reporting owner

Deschatelets Pascal

Relationship: Chief Scientific Officer
Address: C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Signature date: 30 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Award

Transaction value: $0
Shares: +25,840
Change %: +2.2%
Price: $0.000000
Shares after: 1,177,222
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.